MIND-4

CAS No. 1639965-26-6

MIND-4( MIND4 | MIND 4 )

Catalog No. M12482 CAS No. 1639965-26-6

MIND-4 is a novel potent, selective, non-competitive SIRT2 deacetylase inhibitor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 873 Get Quote
50MG 1782 Get Quote
100MG 2250 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    MIND-4
  • Note
    Research use only, not for human use.
  • Brief Description
    MIND-4 is a novel potent, selective, non-competitive SIRT2 deacetylase inhibitor.
  • Description
    MIND-4 is a novel potent, selective, non-competitive SIRT2 deacetylase inhibitor with IC50 of 1.2 uM, Ki of 2.1 uM, and also is an inducer of the NRF2 pathway; upregulates the acetylation of nuclear H3 histone substrates lysine-56 and -27 in wild-type primary cortical neurons (DIV11) without effect on lysine-14 of H3 histone, induces transcriptional activation of the NRF2 pathway in HD and wild-type neuronal cells; significantly protects against mHTTex1-induced neurodegeneration in HD models.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    MIND4 | MIND 4
  • Pathway
    Chromatin/Epigenetic
  • Target
    Sirtuin
  • Recptor
    Sirtuin
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1639965-26-6
  • Formula Weight
    455.492
  • Molecular Formula
    C24H17N5O3S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=[N+](C1=C2C=CC=NC2=C(SC3=NN=C(COC4=CC=CC=C4)N3C5=CC=CC=C5)C=C1)[O-]
  • Chemical Name
    5-nitro-8-((5-(phenoxymethyl)-4-phenyl-4H-1,2,4-triazol-3-yl)thio)quinoline

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Quinti L, et al. Cell Chem Biol. 2016 Jul 21;23(7):849-61.
molnova catalog
related products
  • FIIN-3

    FIIN-3 is an irreversible inhibitor of FGFR.

  • Pristimerin

    Pristimerin has anticancer activity, treatment with Pristimerin may be a potential strategy for the suppression of hypoxia-induced metastasis through the reversal of hypoxia-induced stem cell characteristics and EMT in cancer cells.

  • YK-3-237

    A novel small molecule sirtuin-1 (SIRT1) activator that reduces acetylation of mutant 53 and exhibits anti-proliferative effects against TNBC cells carrying mutant p53.